Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia

Alemtuzumab serum levels and clinical response after subcutaneous administration (10 mg 3 times/week for six weeks) have been explored in 29 chronic lymphocytic leukemia patients receiving the monoclonal antibody as consolidation. Serum concentrations after each administration gradually increased du...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Montagna, Michela, Montillo, Marco, Avanzini, Maria A., Tinelli, Carmine, Tedeschi, Alessandra, Visai, Livia, Ricci, Francesca, Vismara, Eleonora, Morra, Enrica, Regazzi, Mario
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Ferrata Storti Foundation 2011
Konular:
Brief Reports
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3105658/
https://ncbi.nlm.nih.gov/pubmed/21330330
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2010.033159
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller